论文部分内容阅读
目的:探讨血清P-Cadherin、CK-19和MMP-9水平在甲状腺乳头状癌患者中的变化及其临床意义。方法:采用ELISA检测42例甲状腺乳头状癌患者和42例甲状腺良性肿瘤患者血清P-Cadherin、CK-19和MMP-9浓度,并以42例健康人作为对照。结果:血清P-Cadherin、CK-19和MMP-9水平以甲状腺乳头状癌最高,甲状腺良性肿瘤居中,正常人最低,三者差异有显著性(F=15.924,F=18.254,F=12.447,均P<0.01);甲状腺乳头状癌伴淋巴结转移患者比无伴淋巴结转移患者血P-Cadherin、CK-19和MMP-9水平显著升高(t=9.92,t=7.83,t=12.47,均P<0.01);血清P-Cadherin、CK-19和MMP-9水平呈高度正相关(r=0.547,r=0.615,均P<0.01),血清P-Cadherin与CK-19表达也呈高度正相关(r=0.784,P<0.01)。结论:血清P-Cadherin、CK-19和MMP-9对于甲状腺乳头状癌的鉴别诊断具有重要的临床意义,而且对于甲状腺乳头状癌伴淋巴结转移的诊断具有一定的指导作用。
Objective: To investigate the changes of serum P-Cadherin, CK-19 and MMP-9 levels in patients with papillary thyroid carcinoma and its clinical significance. Methods: The serum concentrations of P-Cadherin, CK-19 and MMP-9 in 42 cases of thyroid papillary carcinoma and 42 cases of thyroid benign tumor were detected by ELISA, and 42 healthy controls were used as controls. Results: Serum levels of P-Cadherin, CK-19 and MMP-9 were highest in thyroid papillary carcinomas, benign thyroid tumors and normal ones, the difference was statistically significant (F = 15.924, F = 18.254, F = 12.447, P <0.01). The levels of P-Cadherin, CK-19 and MMP-9 in patients with papillary thyroid carcinoma and lymph node metastasis were significantly higher than those without lymph node metastasis (t = 9.92, t = 7.83, t = 12.47, P <0.01). Serum levels of P-Cadherin, CK-19 and MMP-9 were positively correlated with each other (r = 0.547, r = 0.615, (R = 0.784, P <0.01). Conclusion: Serum levels of P-Cadherin, CK-19 and MMP-9 have important clinical significance for the differential diagnosis of papillary thyroid carcinoma, and may be helpful for the diagnosis of papillary thyroid carcinoma with lymph node metastasis.